Dependent nonagenarians ‘don’t fare worse’ after EVT

Pharma funding: which specialties accept the most payments?

Australian trial shows potential for repair and remyelination in MS

Why the pathology bulk-billing campaign is more about driving industry profits than saving you money

Pharmacogenomic testing guidance to prevent adverse events

Seizure prophylaxis ‘has small effect’ for mild TBI patients

MORE NEWS

more news